Sickle Cell News Mixed

Good News: A new collaboration is seeking to upend the current gene therapies approach for sickle cell disease. Today’s therapies are individualized, extremely complex and hugely expensive, STAT reports.
 
But a new joint effort—from Novartis and the Gates Foundation—aims for a single step treatment, especially in sub-Saharan Africa, home to 80% of those affected by the disease.

Bad News: A gene therapy trial for the disease has been shut down after 2 participants developed a leukemia-like cancer, Science reports.
 
Researchers are investigating whether the cancers may have been caused by a virus used to deliver the therapeutic gene or if the cancers were linked to chemotherapy they received before  the therapy.
 

Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top